196 related articles for article (PubMed ID: 31426803)
1. First-in-human study of TK-positive oncolytic vaccinia virus delivered by adipose stromal vascular fraction cells.
Minev BR; Lander E; Feller JF; Berman M; Greenwood BM; Minev I; Santidrian AF; Nguyen D; Draganov D; Killinc MO; Vyalkova A; Kesari S; McClay E; Carabulea G; Marincola FM; Butterfield LH; Szalay AA
J Transl Med; 2019 Aug; 17(1):271. PubMed ID: 31426803
[TBL] [Abstract][Full Text] [Related]
2. Oncolytic efficacy of thymidine kinase-deleted vaccinia virus strain Guang9.
Deng L; Fan J; Ding Y; Zhang J; Zhou B; Zhang Y; Huang B
Oncotarget; 2017 Jun; 8(25):40533-40543. PubMed ID: 28465492
[TBL] [Abstract][Full Text] [Related]
3. Safety, biodistribution and viral shedding of oncolytic vaccinia virus TG6002 administered intravenously in healthy beagle dogs.
Béguin J; Gantzer M; Farine I; Foloppe J; Klonjkowski B; Maurey C; Quéméneur É; Erbs P
Sci Rep; 2021 Jan; 11(1):2209. PubMed ID: 33500518
[TBL] [Abstract][Full Text] [Related]
4. Targeting of interferon-beta to produce a specific, multi-mechanistic oncolytic vaccinia virus.
Kirn DH; Wang Y; Le Boeuf F; Bell J; Thorne SH
PLoS Med; 2007 Dec; 4(12):e353. PubMed ID: 18162040
[TBL] [Abstract][Full Text] [Related]
5. Use of a targeted oncolytic poxvirus, JX-594, in patients with refractory primary or metastatic liver cancer: a phase I trial.
Park BH; Hwang T; Liu TC; Sze DY; Kim JS; Kwon HC; Oh SY; Han SY; Yoon JH; Hong SH; Moon A; Speth K; Park C; Ahn YJ; Daneshmand M; Rhee BG; Pinedo HM; Bell JC; Kirn DH
Lancet Oncol; 2008 Jun; 9(6):533-42. PubMed ID: 18495536
[TBL] [Abstract][Full Text] [Related]
6. A phase 1b study of intraperitoneal oncolytic viral immunotherapy in platinum-resistant or refractory ovarian cancer.
Manyam M; Stephens AJ; Kennard JA; LeBlanc J; Ahmad S; Kendrick JE; Holloway RW
Gynecol Oncol; 2021 Dec; 163(3):481-489. PubMed ID: 34686353
[TBL] [Abstract][Full Text] [Related]
7. Correlative analysis from a phase I clinical trial of intrapleural administration of oncolytic vaccinia virus (Olvi-vec) in patients with malignant pleural mesothelioma.
Chintala NK; Choe JK; McGee E; Bellis R; Saini JK; Banerjee S; Moreira AL; Zauderer MG; Adusumilli PS; Rusch VW
Front Immunol; 2023; 14():1112960. PubMed ID: 36875061
[TBL] [Abstract][Full Text] [Related]
8. Delivery of oncolytic vaccinia virus by matched allogeneic stem cells overcomes critical innate and adaptive immune barriers.
Draganov DD; Santidrian AF; Minev I; Nguyen D; Kilinc MO; Petrov I; Vyalkova A; Lander E; Berman M; Minev B; Szalay AA
J Transl Med; 2019 Mar; 17(1):100. PubMed ID: 30917829
[TBL] [Abstract][Full Text] [Related]
9. Phase 3 Efficacy Trial of Modified Vaccinia Ankara as a Vaccine against Smallpox.
Pittman PR; Hahn M; Lee HS; Koca C; Samy N; Schmidt D; Hornung J; Weidenthaler H; Heery CR; Meyer TPH; Silbernagl G; Maclennan J; Chaplin P
N Engl J Med; 2019 Nov; 381(20):1897-1908. PubMed ID: 31722150
[TBL] [Abstract][Full Text] [Related]
10. Phase 1b Trial of Biweekly Intravenous Pexa-Vec (JX-594), an Oncolytic and Immunotherapeutic Vaccinia Virus in Colorectal Cancer.
Park SH; Breitbach CJ; Lee J; Park JO; Lim HY; Kang WK; Moon A; Mun JH; Sommermann EM; Maruri Avidal L; Patt R; Pelusio A; Burke J; Hwang TH; Kirn D; Park YS
Mol Ther; 2015 Sep; 23(9):1532-40. PubMed ID: 26073886
[TBL] [Abstract][Full Text] [Related]
11. First-in-man study of western reserve strain oncolytic vaccinia virus: safety, systemic spread, and antitumor activity.
Zeh HJ; Downs-Canner S; McCart JA; Guo ZS; Rao UN; Ramalingam L; Thorne SH; Jones HL; Kalinski P; Wieckowski E; O'Malley ME; Daneshmand M; Hu K; Bell JC; Hwang TH; Moon A; Breitbach CJ; Kirn DH; Bartlett DL
Mol Ther; 2015 Jan; 23(1):202-14. PubMed ID: 25292189
[TBL] [Abstract][Full Text] [Related]
12. Phase I Study of Oncolytic Vaccinia Virus GL-ONC1 in Patients with Peritoneal Carcinomatosis.
Lauer UM; Schell M; Beil J; Berchtold S; Koppenhöfer U; Glatzle J; Königsrainer A; Möhle R; Nann D; Fend F; Pfannenberg C; Bitzer M; Malek NP
Clin Cancer Res; 2018 Sep; 24(18):4388-4398. PubMed ID: 29773661
[No Abstract] [Full Text] [Related]
13. A novel genetically modified oncolytic vaccinia virus in experimental models is effective against a wide range of human cancers.
Haddad D; Chen N; Zhang Q; Chen CH; Yu YA; Gonzalez L; Aguilar J; Li P; Wong J; Szalay AA; Fong Y
Ann Surg Oncol; 2012 Jul; 19 Suppl 3():S665-74. PubMed ID: 22258815
[TBL] [Abstract][Full Text] [Related]
14. IL-21 arming potentiates the anti-tumor activity of an oncolytic vaccinia virus in monotherapy and combination therapy.
Chen T; Ding X; Liao Q; Gao N; Chen Y; Zhao C; Zhang X; Xu J
J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33504576
[TBL] [Abstract][Full Text] [Related]
15. Efficient colonization and therapy of human hepatocellular carcinoma (HCC) using the oncolytic vaccinia virus strain GLV-1h68.
Gentschev I; Müller M; Adelfinger M; Weibel S; Grummt F; Zimmermann M; Bitzer M; Heisig M; Zhang Q; Yu YA; Chen NG; Stritzker J; Lauer UM; Szalay AA
PLoS One; 2011; 6(7):e22069. PubMed ID: 21779374
[TBL] [Abstract][Full Text] [Related]
16. Antiangiogenic arming of an oncolytic vaccinia virus enhances antitumor efficacy in renal cell cancer models.
Guse K; Sloniecka M; Diaconu I; Ottolino-Perry K; Tang N; Ng C; Le Boeuf F; Bell JC; McCart JA; Ristimäki A; Pesonen S; Cerullo V; Hemminki A
J Virol; 2010 Jan; 84(2):856-66. PubMed ID: 19906926
[TBL] [Abstract][Full Text] [Related]
17. Intratumoral OH2, an oncolytic herpes simplex virus 2, in patients with advanced solid tumors: a multicenter, phase I/II clinical trial.
Zhang B; Huang J; Tang J; Hu S; Luo S; Luo Z; Zhou F; Tan S; Ying J; Chang Q; Zhang R; Geng C; Wu D; Gu X; Liu B
J Immunother Cancer; 2021 Apr; 9(4):. PubMed ID: 33837053
[TBL] [Abstract][Full Text] [Related]
18. Systemic cancer therapy with a tumor-selective vaccinia virus mutant lacking thymidine kinase and vaccinia growth factor genes.
McCart JA; Ward JM; Lee J; Hu Y; Alexander HR; Libutti SK; Moss B; Bartlett DL
Cancer Res; 2001 Dec; 61(24):8751-7. PubMed ID: 11751395
[TBL] [Abstract][Full Text] [Related]
19. Vaccinia virus-mediated intra-tumoral expression of matrix metalloproteinase 9 enhances oncolysis of PC-3 xenograft tumors.
Schäfer S; Weibel S; Donat U; Zhang Q; Aguilar RJ; Chen NG; Szalay AA
BMC Cancer; 2012 Aug; 12():366. PubMed ID: 22917220
[TBL] [Abstract][Full Text] [Related]
20. Transient Inhibition of PI3Kδ Enhances the Therapeutic Effect of Intravenous Delivery of Oncolytic Vaccinia Virus.
Ferguson MS; Chard Dunmall LS; Gangeswaran R; Marelli G; Tysome JR; Burns E; Whitehead MA; Aksoy E; Alusi G; Hiley C; Ahmed J; Vanhaesebroeck B; Lemoine NR; Wang Y
Mol Ther; 2020 May; 28(5):1263-1275. PubMed ID: 32145202
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
